Literature DB >> 2337905

Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.

E Lotzová1, C A Savary, R S Freedman, C L Edwards, M Morris.   

Abstract

We have compared the growth and tumor-directed cytotoxic efficacy of recombinant-interleukin-2-(rIL-2)-activated peripheral blood (PBL) and tumor-infiltrating lymphocytes (TIL) from patients with epithelial ovarian carcinoma. These studies demonstrated that TIL and PBL displayed similar levels of cytotoxicity and a broad range of target cell killing, as exemplified by their reactivity against autologous and allogeneic ovarian tumors as well as against tumor cell lines. No specificity of autologous tumor cell killing was manifested by TIL. Even though TIL of some patients showed higher proliferative activity (especially at the later times in rIL-2 culture) this was not a general phenomenon. In fact, in one case TIL did not proliferate at all, and in the other case the PBL proliferated more actively. While the cultures were composed primarily of CD3+ lymphocytes, the major cytotoxic cells displayed the CD56+ and CD16+ phenotype. Addition of OKT3 mAb to rIL-2 cultures resulted in an increased proliferative index, but showed only a minor effect on the cytotoxic potential of cultured lymphocytes. The therapeutic potential of rIL-2-activated TIL and PBL is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337905     DOI: 10.1007/bf01744732

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Altered activation pathways in T lymphocytes infiltrating human solid tumors.

Authors:  S Miescher; M Stoeck; T L Whiteside; S Leyvraz; J Ruzicka; A M Schindler; J C Givel; F Mosimann; V von Fliedner
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

2.  Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. II. Functional investigations of the infiltrating inflammatory cells.

Authors:  T H Tötterman; P Häyry; E Saksela; T Timonen; B Eklund
Journal:  Eur J Immunol       Date:  1978-12       Impact factor: 5.532

3.  Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells.

Authors:  B M Vose; F Vánky; E Klein
Journal:  Int J Cancer       Date:  1977-12-15       Impact factor: 7.396

4.  A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses.

Authors:  E Kedar; B L Ikejiri; G D Bonnard; R B Herberman
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

5.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

6.  Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors.

Authors:  P M Moy; E C Holmes; S H Golub
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

7.  Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.

Authors:  D S Heo; T L Whiteside; A Kanbour; R B Herberman
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

8.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

9.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  2 in total

1.  P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.

Authors:  B Savas; S P Cole; T Tsuruo; H F Pross
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

2.  Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

Authors:  E Halapi; Y Yamamoto; C Juhlin; M Jeddi-Tehrani; J Grunewald; R Andersson; C Hising; G Masucci; H Mellstedt; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.